WARSAW, Ind., Nov. 17,
2016 /PRNewswire/ -- Zimmer Biomet Holdings, Inc. (NYSE and SIX:
ZBH), a global leader in musculoskeletal healthcare, today
announced the launch of the Comprehensive® Vault Reconstruction
System (VRS), the first patient-matched glenoid implant cleared to
specifically treat patients with a severely deficient rotator cuff
and extensive bone loss which precludes the use of a standard
glenoid baseplate. The VRS uses CT imaging and advanced 3D
reconstruction techniques to allow surgeons to personalize each
patient's implant.
"The treatment options for extensive glenoid deficiencies were
limited to bone grafting or hemi-arthroplasties, both of which were
unreliable and had marginal success," said Dr. David Dines, Orthopedic Surgeon at the Hospital
for Special Surgery in New York
and Professor of Orthopedic Surgery at Weill Cornell Medical
College. "The Comprehensive Vault Reconstruction System
represents an important advance in shoulder reconstruction by
streamlining and personalizing the implant procedure in hope of
more predictable outcomes and results that extend beyond pain
relief, to restoring function and improving overall quality of
life."
The first implantation of the VRS took place on September 21, 2016, at the University of Virginia Hospital in Charlottesville, Va. and was successfully
performed by Dr. Stephen
Brockmeier.
"The Comprehensive Vault Reconstruction System is another
example of our commitment to addressing the clinical and unmet
needs of shoulder specialists," said Orsa
Britton, Vice President and General Manager of Zimmer
Biomet's global Extremities business. "This innovative,
patient-specific implant, coupled with extensive pre-operative
planning software, will expand viable treatment options for
patients with severe glenoid deformities."
About Zimmer Biomet
Founded in 1927 and headquartered in Warsaw, Indiana, Zimmer Biomet is a global
leader in musculoskeletal healthcare. We design, manufacture and
market orthopaedic reconstructive products; sports medicine,
biologics, extremities and trauma products; office based
technologies; spine, craniomaxillofacial and thoracic products;
dental implants; and related surgical products.
We collaborate with healthcare professionals around the globe to
advance the pace of innovation. Our products and solutions help
treat patients suffering from disorders of, or injuries to, bones,
joints or supporting soft tissues. Together with healthcare
professionals, we help millions of people live better lives.
We have operations in more than 25 countries around the world
and sell products in more than 100 countries. For more information,
visit www.zimmerbiomet.com or follow Zimmer Biomet on Twitter at
www.twitter.com/zimmerbiomet.
Cautionary Statement Regarding Forward-Looking
Statements
This news release contains forward-looking statements within
the meaning of the safe harbor provisions of the Private Securities
Litigation Reform Act of 1995. Forward-looking statements
include, but are not limited to, statements concerning Zimmer
Biomet's expectations, plans, prospects, and product and service
offerings, including new product launches and potential clinical
successes. Such statements are based upon the current beliefs
and expectations of management and are subject to significant risks
and uncertainties that could cause actual outcomes and results to
differ materially. For a list and description of some of such
risks and uncertainties, see our periodic reports filed with the
SEC. These factors should not be construed as exhaustive and
should be read in conjunction with the other cautionary statements
that are included in Zimmer Biomet's filings with the SEC. We
disclaim any intention or obligation to update or revise any
forward-looking statements, whether as a result of new information,
future events or otherwise, except as may be set forth in our
periodic reports. Accordingly, such forward-looking
statements speak only as of the date made. Readers of this
news release are cautioned not to place undue reliance on these
forward-looking statements, since, while management believes the
assumptions on which the forward-looking statements are based are
reasonable, there can be no assurance that these forward-looking
statements will prove to be accurate. This cautionary
statement is applicable to all forward-looking statements contained
in this news release.
Logo -
http://photos.prnewswire.com/prnh/20150624/225371LOGO
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/zimmer-biomet-announces-launch-of-the-comprehensive-vault-reconstruction-system--the-first-commercially-available-patient-matched-glenoid-implant-300350519.html
SOURCE Zimmer Biomet Holdings, Inc.